Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis by Ibeas, Elvira et al.
Secreted phospholipase A2 type IIA as a mediator
connecting innate and adaptive immunity: new
role in atherosclerosis
Elvira Ibeas†, Lucı´a Fuentes†, Rube´n Martı´n, Marita Herna´ndez, and Maria Luisa Nieto*
Instituto de Biologı´a y Gene´tica Molecular, Consejo Superior de Investigaciones Cientı´ﬁcas/Universidad de Valladolid, C/ Sanz
y Fores s/n., 47005 Valladolid, Spain
Received 3 December 2007; revised 29 July 2008; accepted 22 August 2008; online publish-ahead-of-print 28 August 2008
Time for primary review: 23 days
Aims Human atherosclerotic plaques express markers of macrophage/dendritic cells as well as high
levels of inﬂammatory proteins such as secreted phospholipase A2 type IIA (sPLA2-IIA). To understand
the cellular changes associated with the progress of atherosclerosis, we evaluated the role of sPLA2-
IIA in mediating monocyte recruitment and differentiation into antigen-presenting cells.
Methods and results The effect of sPLA2-IIA on monocyte differentiation was evaluated in human THP-1
cells, a cellular line widely used as a model for monocyte–macrophage differentiation. Changes in func-
tional processes, morphology and expression of antigens, characteristic of differentiated cells, were
monitored over a 1–3 day period. sPLA2-IIA inhibited CD14 expression in a time- and concentration-
dependent manner and upregulated dendritic cell-speciﬁc ICAM-3 grabbing non-integrin levels at the
cell surface, ﬁndings that were the same for human monocytes. In addition, sPLA2-IIA-differentiated
cells showed a dendritic cell phenotype characterized by the generation of ﬁne dendritic protrusions
and an increase in surface markers such as CD40, CD83, CD54, CD61, and CD62L. Furthermore, cell
adhesion, migration, endocytic activity, and allogeneic T cell proliferation capacity were markedly
increased after sPLA2-IIA treatment.
Conclusion sPLA2-IIA induces the differentiation of mononuclear cells and increases their adhesive and
migratory capabilities, which suggests a novel function for sPLA2-IIA as a mediator connecting innate and
adaptive immunity. These ﬁndings may provide insight into the immuno-inﬂammatory processes occur-
ring in atherosclerosis, helping us to understand the cellular changes associated with the development
of atherosclerosis.
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1. Introduction
Atherosclerosis is a complex process characterized by lipid
accumulation in the arterial wall, and it is accompanied by
a local inﬂammatory response in which innate and adaptive
immune mechanisms play key roles in plaque formation.1–3
The inﬂammatory response is mediated by functional
changes in endothelial cells, T lymphocytes, monocytes/
macrophages, and smooth muscle cells (SMC).4 Recently,
dendritic cells (DCs), derived from monocyte precursors,
have also been reported to participate in the atherosclerotic
process by activating T cells.5,6 Their occurrence in
atherosclerotic lesions, as well as in the healthy intima,
predisposes them to the development of atherosclerosis,
as it has been demonstrated in both human and animal
models.7–9 In keeping with this, the expression of DC
markers, including CD80 or DC-SIGN (dendritic cell-speciﬁc
ICAM-3 grabbing non-integrin), has been shown in human
atherosclerotic plaques.10 And, since these markers
mediate adhesion and endocytosis, a fundamental aspect
of DC function, it has been suggested that their expression
may potentially have critical functional implications.
In their immature form, DCs are equippedwith receptors to
become activated when exposed to pathogen-associated
molecular patterns. After antigen uptake, DCs migrate and
differentiate to phenotypically and functionally mature
DCs. These DCs, depending on the maturation state and the
local microenvironment, may act to induce immunological
tolerance and/or regulation ofTcell-mediated immunity.11–13
A multitude of signals, including bacterial components
such as LPS, or pro-inﬂammatory factors such as TNFa or
IL-1b, can promote the maturation of DCs inducing a
switch from an immature stage to a stage of strong T cell-
stimulatory capacity.14 Current studies with enzymes from
bee venom, such as secreted phospholipase A2 type III
(sPLA2-III), have indicated that sPLA2-III can also act on DC† These two authors contributed equally to this work.
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membranes mobilizing lipid mediators and inducing their
maturation.15
Mammalian-secreted PLA2s present many catalytic and
structural similarities with venom phospholipases, they are
extracellular low-molecular-mass (13–18 kDa) enzymes that
have 6–8 disulphide bridges, and require millimolar concen-
trationsofCa2þ forenzymaticactivity.16 Theplasmaofpatients
with various inﬂammatory diseases, particularly atherosclero-
sis, contains high concentrations of the isoform sPLA2-IIA, and
clinical studies reveal a correlation between circulating
levels of the phospholipase and vascular complications.17
sPLA2-IIA, which can be upregulated by inﬂammatory cyto-
kines, such as IL-1b, IL-6, and TNFa, acts as an acute phase
reactant in chronic inﬂammatory diseases and it is clearly
linked to the development of atherosclerotic lesions.18,19 It
has been detected in atherosclerotic arteries and may
trigger its effects on all the atheroma-associated cells.
sPLA2-IIA is present in VSMC from both media and intima
layers and in macrophage-rich regions of atherosclerotic
plaques, and it may induce foam cell formation and low-
density lipoprotein modiﬁcation.20,21 To date, details of
sPLA2-IIA actions and its precise physiological and/or patho-
physiological role have not yet been deﬁned. Although this
enzyme is involved in the speciﬁc synthesis of lysophosphati-
dic acid, unesteriﬁed fatty acids, and prostaglandins, and
most of its biological activities have been attributed to its
capacity to generate biologically active lipids, which may
sustain inﬂammation, several lines of evidence suggest a
mechanism of action involving the human M-type receptor,
or a related structure, as the mediator of its effects.22–24
In this work, we examined the role of sPLA2-IIA in mono-
cyte biology and we found that sPLA2-IIA can act on THP-1
cells to induce a monocyte-derived dendritic cell (MDDC)
phenotype, emphasizing the role of this secreted enzyme
in the regulation of immune responses and its implication
in atherosclerotic processes.
2. Methods
2.1 Materials
A C127 mouse ﬁbroblast cell line stably transfected with the coding
sequence of sPLA2-IIA from human placenta was used as a source of
human recombinant enzyme. sPLA2-IIA was puriﬁed as described
previously.23 FITC-phalloidin, FITC-dextran, PMA, and other chemi-
cals were from Sigma Chemical Co. (St Louis, MO, USA). Recombi-
nant TNFa and IL-4 were from Calbiochem. Monoclonal
anti-human DC-SIGN was a generous gift from Dr A.L. Corbı´
(Centro de Investigaciones Biologicas, CSIC, Madrid, Spain).
2.2 Cell culture
THP-1 cells were cultured at 378C under 5% CO2 atmosphere in RPMI
1640 (GIBCO) with 100 U/mL penicillin/streptomycin, 2 mM gluta-
mine, and 5% FCS and maintained around 5  105 cells/mL.
2.3 Cell isolation from peripheral blood and
monocyte-derived dendritic cell generation
Human monocytes were puriﬁed and differentiated according to
standard procedures.25 Brieﬂy, peripheral blood mononuclear cells
were isolated from fresh buffy coats (provided by the Center for
Hemotherapy of Castilla y Leo´n) by lymphoprep density-gradient
centrifugation. Then, cells were washed and centrifuged at
1500 r.p.m. to avoid platelets. After 1 h of plastic adherence at
378C in RPMI 1640 with 10% FCS, non-adherent cells were removed
by various vigorous washes with PBS and used as T cells in the
mixed-leucocyte reaction (MLR) assay. The remaining adherent
cells were subsequently differentiated with 1 mg/mL sPLA2-IIA or
0.2 mM of PMA þ 1000 U/mL of IL4 for the indicated days.
2.4 FITC-dextran uptake by mononuclear cells
Human THP-1 cells or human monocytes were incubated with
vehicle, 1 mg/mL sPLA2-IIA, 0.2 mM of PMA, or 0.2 mM of PMA þ
1000 U/mL of IL4. After 72 h, cells were suspended in culture
medium with 1 mg/mL FITC-dextran (MW 40 000) and incubated at
48C (for background control) or at 378C for 30 min. Then, cells
were washed with cold PBS containing 1% FCS, and the FITC-dextran
incorporated was analysed by ﬂow cytometry in an EPICSw XL-MCL
cytoﬂuorometer (Coulter). The endocytic activity is expressed as
the mean ﬂuorescence intensity (MFI) index. MFI index is calculated
as ﬂuorescence of FITC-positives cells at 378C minus ﬂuorescence of
FITC-positive cells at 48C and normalized at 100 for the control.
2.5 Flow cytometry
THP-1 cells were analysed for CD 11b, CD11a, CD11c, CD1a, CD83,
CD40, CD14, CD61, CD62L, DC-SIGN, or ICAM expression (Pharmin-
gen, San Diego, CA, USA). Control and treated cells were collected
for immunolabelling with 10 mg/mL of each indicated antibody for
1 h at 48C, followed by PE- or FITC-conjugated secondary antibody
(Sigma). Subsequently, cells were washed, resuspended in 500 mL
of PBS and analysed by ﬂow cytometry. Positive cells were estimated
using P3-X63 myeloma supernatant as a negative control or an
isotype-matched control-negative antibody at an equivalent con-
centration. Data analysis was performed using WinMDI 2.7 software.
2.6 THP-1 cell morphology
THP-1 cells were seeded on glass coverslips (1.2  104 cells/slip).
Then, cells were stimulated for 72 h. After that, cells were washed
with PBS, ﬁxed for 10 min with 3.7% formaldehyde/PBS, and permea-
bilized for 5 min with 0.3% Triton X-100/PBS. Actin morphology was
assessed by staining with FITC-phalloidin and was visualized using a
Bio-Rad laser scanning Radiance 2100 system coupled to a Nikon
Eclipse TE-2000U confocal microscope with a 60 oil objective.
2.7 Assessment of morphological changes
and adhesion assay
Under normal culture conditions, THP-1 cells remain in suspension;
however, after treatment with sPLA2-IIA, a subpopulation of cells
become adherent. Morphological changes of the adherent cells
were assessed by phase-contrast microscopy. In addition, adherent
cells were quantiﬁed by using the [methyl-3H]-thymidine-labelled
adhesion assay. Brieﬂy, THP-1 cells (5  106) were incubated in
RPMI/5% FBS in the presence of [methyl-3H]-thymidine (Amersham,
UK) at a ﬁnal concentration of 0.5 mCi/mL at 378C for 18 h. After
that, cells were washed with PBS and resuspended in RPMI and
then used in the adhesion assay.
The labelled cells were stimulated with 1 mg/mL of sPLA2-IIA,
0.2 mM of PMA, or 0.2 mM of PMA þ 1000 U/mL IL-4 at 378C for the
indicated times. Then, the plates were rinsed four times with
PBS, adherent cells were scraped, and the amount of radioactivity
present was determined by liquid scintillation counting.
2.8 Chemotaxis assay
Chemotaxis assay was performed in a six-well plate using tissue
culture polycarbonate ﬁlter inserts (3 or 8 mm pore, Corning,
Costar, Cambridge, MA, USA) blocked with BSA. THP-1 cells (5 
106) were resuspended in 1 mL of serum-free medium, loaded into
the upper chamber of an insert, and incubated at 378C. The lower
chamber contained conditioned medium from cells incubated with
either vehicle, 100 U/mL of TNF-a, or 1 mg/mL of sPLA2 for 18 h.
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After 45 min, the membrane was removed, and the cells in the
lower chamber were recovered and counted in a cytoﬂuorometer.
The results are expressed as the fold increase over the control.
2.9 Allogeneic mixed-leucocyte reaction: T cell
proliferation assay
The immunostimulatory capacities of the sPLA2-IIA-treated THP-1
cells to activate T cells was measured in an MLR and quantiﬁed by
the MTS assay (Cell Tilter 96TM Non-Radioactive Cell Proliferation
Assay, Promega, Inc.) method, according to the manufacturer’s
recommendations.
THP-1 cells were differentiated for 5 days with 1 mg/mL sPLA2-IIA
or 0.2 mM of PMA þ 1000 U/mL of IL4 (effector cells) and treated
with 50 mg/mL mitomycin C (Sigma) for 20 min at 378C to inhibit
cell proliferation. After extensive washes, various numbers (103,
5  103, 104) of these differentiated THP-1 cells (THP-1-DC) were
added to freshly isolated 104 lymphocytes (responder cells). Tripli-
cates of the co-culture were incubated for 3 days in 96-well round-
bottom microtitre plates, and the proliferative T cell response was
quantiﬁed by the addition of MTS solution (20 mL/well). After 1 h
incubation, the conversion of MTS to formazan was measured at
490 nm in a microplate reader (VERSAmax, Molecular Devices, CA,
USA). As control, lymphocytes were cultured in the absence of
THP-1-DC. For data analysis, the actual absorbance values from
the co-culture were adjusted for the background absorbance of
THP-1-DC. Proliferation index was calculated as the ratio of the cor-
rected absorbance for a speciﬁc experimental condition to the
absorbance of control culture (lymphocytes alone).
2.10 Data presentation
Numerical data are expressed as means+SD and analysed with the
GraphPad Prism Version 4 software (San Diego, CA, USA) for statisti-
cal signiﬁcance using the one-way ANOVA test, followed by Dun-
nett’s multiple comparison test to compare differentiated cells to
untreated control cells. P, 0.05 was considered signiﬁcant.
3. Results
3.1 Secreted phospholipase A2 type IIA promotes
THP-1 monocyte differentiation
We studied the capacity of sPLA2-IIA to modulate monocyte
differentiation into either macrophages or DCs. In order to
Figure 1 Secreted phospholipase A2 type IIA (sPLA2-IIA) reduces the expression of CD14 on THP-1 cells. Cells were treated with 1 mg/mL of sPLA2-IIA for various
time periods at 378C (A) or for 48 h with different doses of sPLA2-IIA (B), and CD14 expression was analysed by ﬂow cytometry (empty black curves) and compared
with isotype controls (solid grey curves). Histograms represent one experiment out of three. The binding of anti-CD14 is expressed as mean ﬂuorescence
intensity. Graphics, mean of three independent experiments + SD; n ¼ 3. *P , 0.01 vs. control untreated cells.
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characterize the phenotypic modiﬁcations elicited by
sPLA2-IIA, we used a well-characterized human promonocy-
tic cell line, THP-1, since these cells have been extensively
considered a valuable model system for monocyte–macro-
phage differentiation and for studying intracellular sPLA2-
IIA-signalling pathways. Thus, THP-1 cells were stimulated
with the phospholipase, and the expression of CD14 was
analysed in the culture after 24, 48, and 72 h by ﬂow cyto-
metry. As shown in Figure 1A, the treatment with 1 mg/mL
sPLA2-IIA triggered a time-dependent downregulatory
effect on CD14 surface expression. To deﬁne the dose-
dependency of the action of the sPLA2-IIA, cells were incu-
bated for 24 h with different concentrations of sPLA2-IIA.
Figure 1B shows the effects of the different concentrations
of sPLA2-IIA on CD14 downregulation. The optimal effect
took place at a concentration of 1 mg/mL sPLA2-IIA,
which is the concentration used in experiments to follow.
Apart from CD14 downregulation, also morphological
changes in THP1 can be observed after incubation with
the phospholipase. Figure 2A illustrates cellular mor-
phology studies under phase-contrast microscopy, where
it is shown that, in the presence of the phospholipase,
cells became adherent, formed homotypic aggregates,
and displayed cytoplasmic protrusions, characteristic mor-
phology of DCs. Cell clustering began 24 h following
sPLA2-IIA stimulation and was further enhanced after 48–
72 h. We also incubated THP-1 cells with PMA þ IL-4,
known to induce phenotypic and functional MDDCs. As
shown in Figure 2A, this treatment yielded similar results
to those found with the phospholipase. Moreover, cells
were stained for F-actin and observed under confocal
(Figure 2B, upper panels) or conventional (Figure 2B,
lower panels) ﬂuorescence microscope; the studies
revealed that sPLA2-IIA-treated THP-1 cells also developed
morphological changes suggestive of MDDC, since they
exhibited numerous projections and a laterally positioned
nucleus, similar to what it is induced after PMA þ IL-4
treatment. In addition, the modulation of CD14 was also
evaluated in ﬂuorescence immunostaining experiments. As
shown in Figure 2C, the signal corresponding to CD14, con-
stitutively expressed in control cells, was barely detectable
after differentiation.
The effect found on CD14 surface expression after
sPLA2-IIA incubation (79% positive cells and 60 MFI) was
similar to that obtained when the cells were incubated in
the presence of the differentiation-inducing agents PMA
and IL-4 (65% positive cells and 50 MFI), compared with
untreated cells (98% positive cells and 175 MFI)
(Figure 3A). Furthermore, DC-SIGN, the C-type lectin
marker of DCs and MDDCs, barely detectable in resting
THP-1 cells (15% positive cells and 20 MFI), was strongly
expressed within 72 h of treatment with sPLA2-IIA (82% posi-
tive cells and 52 MFI) in a manner comparable with what is
observed after PMA and IL-4 (70% positive cells and 85
MFI).25 Next, sPLA2-IIA was added simultaneously to PMA
and IL-4, and ﬂow cytometry analysis revealed minor
effects on both CD14 (62% positive cells and 47 MFI) and
DC-SIGN (86% positive and 60 MFI) expressions, compared
with the induction found after either the combination
PMAþIL-4 or the phospholipase alone (Figure 3A). Interest-
ingly, the same effect was also observed in human mono-
cytes (Figure 3C). The modulation of DC-SIGN was also
evaluated by western blot and by ﬂuorescence immunostain-
ing experiments. As shown in Figure 3B, the signal corre-
sponding to DC-SIGN greatly increased in cells treated with
either sPLA2-IIA or PMA and IL-4 compared with untreated
cells.
To go deeper into the phenotype of sPLA2-IIA-treated
THP-1 monocytes, ﬂow-cytometrical analysis of monocyte/
dendritic surface antigens was performed (Figure 4). The
histograms demonstrate that after sPLA2-IIA stimulation,
cells share immunophenotypic features with PMA þ
IL-4-differentiated THP-1: CD14 was clearly downregulated
and cells increased the level of the expression of the
surface markers CD54 (ICAM-1), CD62L, and CD61, as well
as the costimulatory molecules CD40 and CD83. However,
although no signiﬁcant differences were found in the pre-
sence of CD1a, CD18, CD11a, CD11b, or CD11c at any time
point in sPLA2-IIA-treated cells, the presence of PMA þ
IL-4 led to an upregulation of CD11a, CD11b, CD1a, and
CD18. In addition, neither the membrane mannose receptor
(CD206) nor CD36, both markers of macrophages,
were upregulated by the presence of sPLA2-IIA (data not
shown).
Figure 2 Secreted phospholipase A2 type IIA (sPLA2-IIA) affects the morpho-
logical appearance of THP-1 cells. Cells were plated onto poly-L-lysine-coated
coverslips. After stimulation with 1 mg/mL secreted phospholipase A2 type IIA
or 0.2 mM PMA þ 1000 U/mL IL4 for the indicated times, cells were ﬁxed, and
visualized under a phase contrast microscope (Nikon Eclipse TS100, 20,
40) (A), or labelled with FITC-phalloidin (B) or anti-CD14 antibody (C) and
analysed with a confocal (B, upper panels) or a conventional (B, lower
panels, and C) ﬂuorescence microscope. Images are representative ﬁelds of
cells stimulated for 72 h, the cellular morphology observed using Nomarski
optics.
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3.2 Effects of secreted phospholipase A2 type IIA
on functional cellular processes
3.2.1 Regulation of endocytosis by secreted
phospholipase A2 type IIA
Antigen uptake in immature DCs occurs primarily through
endocytosis, and this ability is critical for the immunological
function of these cells. However, this skill of efﬁcient intern-
alization of antigens is progressively lost during the matura-
tional process, as mature DCs become focused on presenting
antigens.26 To determine the endocytic capacity of both
sPLA2-IIA-treated THP-1 cells (Figure 5A and B) and mono-
cytes (Figure 5C and D), untreated and treated cells were
incubated with the probe FITC-dextran, since it allows quan-
titation by ﬂow cytometry analysis. Figure 5A and C shows
FITC-dextran beads accumulation at 378C in cells differen-
tiated with the indicated agonist. Approximately 80% of
the THP-1 cells became FITC-dextran-positive after 1 h of
incubation with sPLA2-IIA, and 95% after PMA or PMA þ
IL-4 treatment. The narrow distribution of the ﬂuorescence
proﬁle in the histograms indicates that all the cells of a
particular condition take up comparable amounts of the
probe; however, diverse MFI are observed between
treatments owing to different efﬁciency in antigen
capture. Similar behaviour was observed in monocytes,
although in these cells the maximal response was found
after PMA þ IL-4 exposure. For statistical analysis, MFI
values were normalized to 100 of control non-treated cells
(Figure 5B and D).
3.2.2 Regulation of T cell stimulatory capacity: mixed
lymphocyte reaction
Next, to evaluate the antigen-presenting function of sPLA2-
IIA-treated THP-1 cells, their ability to stimulate the pro-
liferation of allogeneic lymphocytes was assessed by the
MLR. As shown in Figure 6A, we found that sPLA2-IIA-treated
THP-1 cells were able to strongly stimulate the proliferation
of lymphocytes, although their antigen-presenting ability
was weaker than that of PMA þ IL4-treated cells. This T
cell stimulatory capacity of the differentiated THP-1 cells
was in line with the phenotypic changes shown previously.
The proliferative response rate correlated with the
THP-1-DC/lymphocytes ratio. When untreated THP-1 cells
were co-cultured with 104 lymphocytes at a ratio of 1:1,
the proliferation index was 1.7+0.3, meaning a 40 and
30% of the T cell proliferation induced by sPLA2-IIA- or
PMA þ IL4-stimulated THP-1 cells, respectively, at the
same ratio. Therefore, sPLA2-IIA generates cells that
possess the capacity to trigger functionally relevant inter-
actions with T lymphocytes.
3.2.3 Regulation of chemotaxis by secreted
phospholipase A2 type IIA
The recruitment of DCs from the site of residence to the T
cell areas is another essential event in the induction of
Figure 3 Secreted phospholipase A2 type IIA (sPLA2-IIA) upregulates dendri-
tic cell-speciﬁc ICAM-3 grabbing non-integrin (DC-SIGN) in human monocytes
and in THP-1 cells. Cells were treated with 1 mg/mL secreted phospholipase
A2 type IIA, 0.2 mM PMA þ 1000 U/mL IL4, or combination of both conditions
for 72 h at 378C. (A) Dendritic cell-speciﬁc ICAM-3 grabbing non-integrin and
CD14 expressions in THP-1 cell were measured by ﬂow cytometry. Solid grey
curves represent unspeciﬁc binding; empty black curves, cells cultured in the
absence of treatment (control); empty grey curves, agonist-treated cells. (B)
THP-1 cells treated as above were either stained with antibodies against
dendritic cell-speciﬁc ICAM-3 grabbing non-integrin and visualized under a
ﬂuorescent microscope (60) or lysed and subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and western blot with an antibody
against dendritic cell-speciﬁc ICAM-3 grabbing non-integrin. (C) Representa-
tive histograms of human monocytes exposed to 1 mg/mL secreted phospho-
lipase A2 type IIA or 0.2 mM PMA þ 1000 U/mL IL4 for 72 h at 378C. Treated
cells (empty black curves) are compared with isotype controls (solid grey
curves).
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primary immune responses, and several lines of evidence
indicate that their migration is promoted by locally pro-
duced inﬂammatory cytokines such as TNFa.27 To determine
the migratory capacity of the cells in response to sPLA2-IIA
or to sPLA2-IIA-produced factors, THP-1 cells were placed
in the upper chambers of Transwell inserts. The lower
chambers contained supernatants from non-stimulated
cells, 24 h sPLA2-IIA-stimulated cells, or 24 h TNFa-stimu-
lated cells. With the 8 mm pore inserts, THP-1 cells
showed a slight preferential migration in response to
supernatants from sPLA2-IIA-stimulated cells, over TNFa-
supernatants, and migrated three-fold above the media
Figure 4 Phenotype of secreted phospholipase A2 type IIA (sPLA2-IIA)-treated cells. THP-1 cells were cultured in the presence of 1 mg/mL secreted phospho-
lipase A2 type IIA or 0.2 mM PMA þ 1000 U/mL IL4 for different times. Histograms represent one experiment out of three and show the expression of the indicated
surface markers analysed by ﬂow cytometry. Solid grey curves represent unspeciﬁc binding; empty black curves, cells cultured in the absence of treatment
(control); empty grey curves, agonist-treated cells.
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control (Figure 6B). With the 3 mm pore inserts, the
migration of THP-1 cells exposed to sPLA2-IIA supernatant
was sensibly diminished, whereas those exposed to TNFa
supernatants showed similar levels of chemotaxis to the
8 mm pore inserts. When the lower chambers contained
media plus sPLA2-IIA, no chemotactic effect was observed.
In addition, we examined the migration of sPLA2-IIA-treated
cells exposed to sPLA2-IIA supernatant, and we observed
that there was no signiﬁcant difference, compared with
cells exposed to control media (data not shown).
3.2.4 Regulation of adherence by secreted
phospholipase A2 type IIA
The differentiation of monocytes to either macrophages or
DC is accompanied by changes in their ability of adhesion
to extracellular matrices. To test the ability of sPLA2-IIA
to affect cell adherence, [3H]-thymidine-labelled THP-1
monocytes were aliquoted into six-well plastic plates and
incubated for 12 or 24 h with the enzyme, PMA þ IL-4, or
PMA alone (as a reference agonist). As shown in Figure 6C,
sPLA2-IIA, as well as PMA or PMA þ IL-4, was found to
Figure 5 Endocytic capacity of secreted phospholipase A2 type IIA (sPLA2-IIA)-treated cells. THP-1 cells (A and B) and human monocytes (C and D) were cultured
in the absence or presence of 1 mg/mL secreted phospholipase A2 type IIA, 0.2 mM PMA, or 0.2 mM PMA þ 1000 U/mL IL4 for 72 h. Then, they were incubated
with FITC-dextran for 1 h and analysed by ﬂow cytometry. (A and C) Histograms represent one experiment out of three. Solid grey curves represent unspeciﬁc
endocytosis and empty black curves endocytosis of cells cultured as indicated. (B and D) Endocytic activity, as indicated in Methods, is expressed as mean
ﬂuorescence intensity index+ SD normalized by setting controls to 100%. *P , 0.05, **P, 0.01 vs. control untreated cells.
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increase, in a time-dependent manner, the adherence of
THP-1 cells to plastic surfaces. Although, PMA- and PMA þ
IL-4-treated THP-1 monocytes showed higher adhesive
ability than sPLA2-IIA-treated cells, after 48 h the adherence
induced by both agents showed similar levels of increase
than at 24 h.
4. Discussion
Inﬂammation plays an important role in atherosclerosis,
contributing to the recruitment of inﬂammatory cells into
the lesions, where they turn into macrophages, foam cells,
or dendritic cells, causing plaque instability, which is the
main process that elicits cardiovascular events. It is well
demonstrated that cardiovascular risk factors, such as
oxidized-LDL, nicotine, or some acute-phase reactants
(APR), cause the modulation of the immune system.28–30
Among APR found enhanced in serum of patients with coron-
ary artery disease, high circulating levels of C-reactive
protein and sPLA2-IIA have been observed, but, although C-
reactive protein role in DC differentiation, maturation, and
functions have been assessed, little is known about how
secreted phospholipases affect this process.30
Several attempts have been performed with bee venom
PLA2 and the catalytic domain of human sPLA2-III on DC
maturation and activation,12,31 but the role in immunity
and/or in the tolerance of the sPLA2 enzymes present in
human inﬂammatory lesions, such as sPLA2-IIA, sPLA2-V, or
sPLA2-X, still has to be addressed. This work is the ﬁrst to
evaluate the potential immunomodulatory effects of the
human sPLA2-IIA. In this study, human THP-1 monocytes,
widely used as a monocyte/macrophage differentiation
model, were characterized following incubation with the
secreted enzyme. We show that, upon treatment, THP-1
cells display the following: (i) upregulation of surface
markers CD83, CD40, DC-SIGN, CD54, CD61, and CD62L; (ii)
downregulation of surface marker CD14; (iii) appearance
of typical dendritic morphological features; (iv) adhesion
and migration; (v) increased endocytic activity; and (vi)
induction of allogeneic lymphocyte proliferation. Therefore,
we conclude that sPLA2-IIA, an enzyme present in the ather-
osclerotic lesions, is able to induce the differentiation of
THP-1 monocytes into MDDCs or, alternatively activated
macrophages, similar to what is observed with the classical
combination of PMA þ IL-4.25 Moreover, the studies that we
performed in human monocytes to validate these responses
conﬁrmed that the differentiation activity of the phospho-
lipase is not restricted to THP-1 cells.
Previously, it had been suggested that the participation of
inﬂammatory-secreted PLA2s, including group IIA, V, or X, on
DC maturation in vivo, is due to their ability to modify LDL,
rather than phospholipases themselves.32,33 However, here
we show that it is the action of sPLA2-IIA itself on THP-1
monocytes which promotes the phenotypic and morphologi-
cal modiﬁcations.
In atherosclerotic arteries, sPLA2-IIA occurs in both cellu-
lar and extracellular elements, and it has been found associ-
ated to SMC and macrophages/foam cells.20 Therefore, we
can hypothesize that sPLA2-IIA released by SMC may induce
a dendritic cell-like phenotype in adjacent monocytes/
macrophages, acting as an ampliﬁer of the inﬂammatory
responses and enabling these cells to present antigens and
support an immune response.
Figure 6 Effect of secreted phospholipase A2 type IIA on functional capabili-
ties of THP-1 cells. (A) T cell stimulatory activity. THP-1 cells were differen-
tiated with 1 mg/mL secreted phospholipase A2 type IIA or 0.2 mM PMA þ
1000 U/mL IL4 for 5 days and treated with mitomycin C. Then, 104 peripheral
blood T lymphocytes were cultured with RPMI alone or with various numbers
of these mitomycin C-treated THP-1 dendritic cells. After a 3 day co-culture,
proliferation was determined using the MTS assay, the proliferation index cal-
culated as described in Methods. Optical density at 490 nm in the culture con-
taining lymphocytes with RPMI alone (control) was 0.175+0.032; n ¼ 3. *P ,
0.001 vs. RPMI alone. (B) The migratory capacity was determined using 3 and
8 mm pore-size Transwell plaques, as indicated in Methods. The results are
presented as a migration index denoting the fold increase of cell migration
over control. *P , 0.001 vs. control. (C) THP-1 adherence was determined
after 12 or 24 h stimulation with solvents (control), 1 mg/mL secreted phos-
pholipase A2 type IIA, 0.2 mM PMA, or 0.2 mM PMA þ 1000 U/mL IL4, as
described in Methods. *P , 0.05, **P , 0.01 vs. control. Each bar represents
mean+ SD (n ¼ 3).
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sPLA2-IIA-treated THP-1 cells are, in many ways, compar-
able with in vitro-differentiated monocytes in the presence
of PMA þ IL-4. They become clustered and develop the
clearly characteristic dendritic morphology, as well as the
capacity to capture FITC-dextran. However, although they
share the basic DC phenotype, the analysis of the expressed
membrane markers demonstrates some differences between
them, for instance, although after PMA þ IL-4 differen-
tiation cells acquire high expression levels of CD11b,
CD11c, CD1a, and CD18, sPLA2-IIA treatment does not
affect their expression.
It has been suggested that depending on the local micro-
environment, MDDC can adopt different membrane-marker
proﬁles, which could have major inﬂuences on cell–cell
interactions and antigen uptake and presentation. Thus,
the absence of CD1a expression has also been found in DCs
derived from human monocytes in the presence of dexa-
methasone.34 In addition, and consistent with the role of
CD1a in the allogenic T cell response, dexamethasone DC
has lower T cell stimulatory activity. In keeping with that,
although we have observed that sPLA2-treated THP-1 cells
present the ability to induce higher lymphocyte prolifer-
ation than resting ones, their allostimulatory function is
weaker than that induced by PMA þ IL4 differentiation,
which also elicits CD1a upregulation.
Another crucial function of DCs is the capacity to capture
exogenous antigens: the endocytic activity. We found that
sPLA2-IIA signiﬁcantly altered the processes of endocytosis
and the expression of some phagocytic receptors on THP-1
cells. The endocytic capacity of sPLA2-IIA-treated cells was
signiﬁcantly enhanced, although at a lower extent than
PMA þ IL-4-differentiated cells. However, the expression of
DC-speciﬁc ICAM-3-grabbing non-integrin was largely upre-
gulated in both conditions. This increase on surface
DC-SIGN expression presents a special relevance, given
that studies on plaques from human coronary and carotid
arteries and aorta reveal the presence of DC-SIGN-immuno-
reactive cells.10 In addition, since this DC-speciﬁc lectin
molecule has been implicated as a receptor used by
various microorganisms associated with chronic infection,
its upregulation on sPLA2-IIA-treated cells may also have
important consequences for pathogen clearance. Thus,
THP-1 differentiation in the presence of sPLA2-IIA at the
sites of inﬂammation may directly play a role in antigen
loading, presentation capabilities, and, therefore, in the
immune response. Interestingly, we (and others) detect
at least three DC-SIGN bands in differentiated cells; it
has been suggested that they may represent differential
glycosylation of a DC-SIGN isoform or be derived from
alternatively spliced mRNA but it is still under
investigation.25
In addition, the observed upregulation of CD83, a typical
marker of DCs, was also recently reported for monocyte-
derived DCs treated with sPLA2-III from bee venom.
12 The
adhesion molecules, CD54 (involved in leucocyte trafﬁcking
towards inﬂammatory stimuli) and CD62L (the homing
receptor), are also increased during the time-course analy-
sis, although CD18, also required for migration, is not modu-
lated. The expression of co-stimulatory molecules, such as
CD40, also increased following 24 h of phospholipase stimu-
lation. Therefore, the expression marker proﬁle induced by
sPLA2-IIA resembles an intermediate stage between imma-
ture and mature MDDC.
It is generally accepted that many types of DCs exist, with
subtle differences in phenotype markers, and there is a wide
array of factors that regulate monocyte differentiation,
playing a critical role on the heterogenous phenotype of
DC. Thus, depending on the presence of speciﬁc cytokines,
monocyte differentiation switches from dendritic cells to
macrophages, or from macrophages to DC.35,36 Factors,
such as cyclic nucleotides, promote monocyte differen-
tiation towards an intermediate cell type between macro-
phages or DCs.37 Even foam cell-inducing agents, such as
native LDL and oxLDL, promote a dendritic cell-like pheno-
type on macrophages.38
In conclusion, this work shows that the immunostimula-
tory activity of secreted phospholipases is not restricted to
the induction of DC maturation, but can also be considered
environmental factors, at the inﬂammatory site, that affect
the differentiation process of monocytes, playing a crucial
role in the interface among innate and adaptive immunity.
Increased PLA2 levels in atherosclerotic arteries may be a
critical factor to regulate dendritic cell formation in lesions
favouring the development of the adaptive arm of immunity
and, in turn, inﬂuencing composition, inﬂammatory nature,
and plaque growth. The regulation of the sPLA2 expression in
the atherosclerotic lesion could be a strategy in order to
avoid plaque instability and, therefore, a worsening of the
prognosis of the pathology.
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